Article
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Blood - 14 May 2015
Nonami Atsushi, Sattler Martin, Weisberg Ellen, Liu Qingsong, Zhang Jianming, Patricelli Matthew P, Christie Amanda L, Saur Amy M, Kohl Nancy E, Kung Andrew L, Yoon Hojong, Sim Taebo, Gray Nathanael S, Griffin James D
Abstract excerpt
Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers, making them important therapeutic targets. Inhibition of individual downstream effector molecules (eg, RAF kinase) have been complicated by the rapid development of resistance or activation of bypass pathways. For the purpose of identifying novel targets in NRAS-transformed cells, we performed a chemical screen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.